AZN•benzinga•
AstraZeneca- Daiichi Sankyo's Multi-Billion Dollar Cancer Drug Shows Superior Efficacy Across Broad HER2 Positive Metastatic Breast Cancer Patients
Summary
AstraZeneca's Enhertu combo improved progression-free survival in HER2+ metastatic breast cancer in a Phase 3 trial, showing promising early results.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on April 21, 2025 by benzinga